Astle Christopher
Known title: SVP & Chief Financial OfficerCIK: 0001915257
Associated companies
Transaction History
| ZYME | ▼ Sell | Open Market | 1,431 | $16K | 1/8/2024 | View on chart |
| ZYME | ▲ Buy | Option Exercise | 10,500 | $0 | 1/5/2024 | View on chart |
| ZYME | ▼ Sell | Open Market | 4,563 | $49K | 1/5/2024 | View on chart |
| ZYME | ▲ Buy | Option Exercise | 1,550 | $0 | 12/11/2023 | View on chart |
| ZYME | ▼ Sell | Open Market | 886 | $8K | 12/11/2023 | View on chart |
| ZYME | ▲ Buy | Option Exercise | 1,550 | $0 | 12/12/2022 | View on chart |
| ZYME | ▼ Sell | Open Market | 887 | $5K | 12/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ZYME News Highlights Potential Undervaluation and Raised Price Target
Recent coverage notes that Zymeworks may be about 39% undervalued based on its 2026 revenue guidance and the recent appointment of a chief investment officer. Truist Securities also kept its rating and lifted its price target to $34, reflecting continued confidence in the company's outlook.
ZYME News Highlights Potential Undervaluation and Raised Price Target. Recent coverage notes that Zymeworks may be about 39% undervalued based on its 2026 revenue guidance and the recent appointment of a chief investment officer. Truist Securities also kept its rating and lifted its price target to $34, reflecting continued confidence in the company's outlook.